1. Scrip
  2. >>Business
  3. >>Deals

Novo Nordisk Calls On Two Flagship Firms For Early Science In Metabolic Health

 
• By Joseph Haas

Derived from a 2022 collaboration between the two, Novo Nordisk will partner with Flagship-backed Omega in obesity and Cellarity in NASH. Both programs are in very early stages at present.

Novo Nordisk HQ
Novo Nordisk has inked the first two deals under its Flagship alliance • Source: Shutterstock

Looking to keep its edge in metabolic health, Novo Nordisk A/S is turning to an agreement signed with Flagship Pioneering and its Pioneering Medicines unit to tap into early stage science, specifically in obesity and non-alcoholic steatohepatitis (NASH), through a pair of research collaborations unveiled on 4 January with Omega Therapeutics, Inc. and Cellarity.

The two deals follow an agreement between Novo Nordisk and the venture capital firm two years ago to accelerate research and development by accessing “the cutting edge technologies and therapeutic modalities” of Flagship’s portfolio companies. The alliance, signed in May 2022, is aimed at generating three to five candidates in cardiometabolic and rare diseases in three years

Key Takeaways

  • Novo Nordisk is building on its 2022 alliance with Flagship Pioneering by partnering in early science in obesity and NASH with two of its companies.

  • Omega will partner with Novo Nordisk on an epigenetic approach to obesity, attempting to harness the natural process of thermogenesis

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

Lilly And Alchemab Tap Into Resilient Individuals To Develop ALS Drug

 
• By Andrew McConaghie

The pharma company is helping to validate the biotech’s model by developing a novel amyotrophic lateral sclerosis candidate, based on its novel approach that ‘turns drug discovery on its head’.

More from Business

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.